SubscribeSign In

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/fda-approves-gsks-rsv-vaccine-for-older-adults-9c2c5

FDA Approves GSK’s RSV Vaccine for Older Adults

Approval of respiratory syncytial virus vaccine is a first for people 60 years and older, company says

By Peter Loftus
RSV is a common virus that can lead to potentially serious respiratory illness. Photo: Associated Press

The U.S. Food and Drug Administration approved the first vaccine against a common respiratory virus in older adults that has been a major cause of hospitalizations and deaths.

The FDA on Wednesday cleared the vaccine from GSK for the prevention of lower respiratory tract diseases such as pneumonia and bronchitis that are caused by respiratory syncytial virus, or RSV, in people 60 and older.

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.